The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the phase III TRIBE trial by GONO group.
Alfredo Falcone
Consultant or Advisory Role - Amgen; Merck Serono; Roche
Honoraria - Amgen; Merck Serono; Roche
Research Funding - Amgen; Merck Serono; Roche
Chiara Cremolini
No relevant relationships to disclose
Gianluca Masi
No relevant relationships to disclose
Sara Lonardi
No relevant relationships to disclose
Vittorina Zagonel
No relevant relationships to disclose
Lisa Salvatore
No relevant relationships to disclose
Patrizia Trenta
No relevant relationships to disclose
Gianluca Tomasello
No relevant relationships to disclose
Monica Ronzoni
No relevant relationships to disclose
Libero Ciuffreda
No relevant relationships to disclose
Alberto Zaniboni
No relevant relationships to disclose
Giuseppe Tonini
No relevant relationships to disclose
Angela Buonadonna
No relevant relationships to disclose
Chiara Valsuani
No relevant relationships to disclose
Silvana Chiara
No relevant relationships to disclose
Chiara Carlomagno
No relevant relationships to disclose
Corrado Boni
No relevant relationships to disclose
Lorenzo Marcucci
No relevant relationships to disclose
Luca Boni
No relevant relationships to disclose
Fotios Loupakis
No relevant relationships to disclose